Immunotherapy in Lung Cancer

>

The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.

Latest News

Jeffrey D. Bradley, MD, vice chair, Proton Therapy & Technology Development, professor, radiation oncology, the Hospital of the University of Pennsylvania
Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC

March 25th 2024

Durvalumab/chemoradiation did not significantly improve survival vs chemoradiation alone in patients with unresectable non–small cell lung cancer.

FDA
FDA Grants Fast Track Designation to UV1 Cancer Vaccine for Unresectable/Metastatic Mesothelioma

February 5th 2024

Vlad Vitoc, MD
Sequential Treatment With Telomere-Targeted Therapy, Checkpoint Inhibition Produces High DCR in NSCLC

January 18th 2024

Helen Torley, MB, ChB, MRCP
European Commission Approves Subcutaneous Atezolizumab With Enhanze for Several Cancers

January 16th 2024

Hossein Borghaei, MS, DO
IO Combos Yield OS Advantage Vs Chemo Alone in Stage IV PD-L1–Negative NSCLC

November 11th 2023

Video Series
Video Interviews
Podcasts

More News